These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19805684)

  • 1. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.
    Theman TA; Hartzell TL; Sinha I; Polson K; Morgan J; Demetri GD; Orgill DP; George S
    J Clin Oncol; 2009 Nov; 27(33):e198-200. PubMed ID: 19805684
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
    Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
    J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin.
    Grosso F; D'Incalci M
    Tumori; 2011; 97(2):256. PubMed ID: 21617728
    [No Abstract]   [Full Text] [Related]  

  • 4. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity.
    Stoyianni A; Kapodistrias N; Kampletsas E; Pentheroudakis G; Pavlidis N
    Tumori; 2011; 97(2):252-5. PubMed ID: 21617727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
    Blay JY; Casali P; Nieto A; Tanović A; Le Cesne A
    Future Oncol; 2014 Jan; 10(1):59-68. PubMed ID: 23987833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
    Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
    Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
    Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
    Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
    J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extravasation of chemotherapeutic agents.
    Hankin FM; Louis DS
    Am Fam Physician; 1985 Mar; 31(3):147-50. PubMed ID: 3976457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
    Saponara M; Stacchiotti S; Gronchi A
    Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
    Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
    Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.
    Haslik W; Hacker S; Felberbauer FX; Thallinger C; Bartsch R; Kornauth C; Deutschmann C; Mader RM
    Eur J Surg Oncol; 2015 Mar; 41(3):378-85. PubMed ID: 25515823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.
    Martinez-Trufero J; Alfaro J; Felipo F; Alvarez M; Madani J; Cebollero A
    Anticancer Drugs; 2010 Sep; 21(8):795-8. PubMed ID: 20622667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.
    Skorupa A; Beldner M; Kraft A; Montero AJ
    Cancer Biol Ther; 2007 Jul; 6(7):1015-7. PubMed ID: 17611408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
    Grosso F; Sanfilippo R; Virdis E; Piovesan C; Collini P; Dileo P; Morosi C; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Pilotti S; Casali PG
    Ann Oncol; 2009 Aug; 20(8):1439-44. PubMed ID: 19465423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: a multicentric Italian experience.
    Martella F; Salutari V; Marchetti C; Pisano C; Di Napoli M; Pietta F; Centineo D; Caringella AM; Musella A; Fioretto L
    Anticancer Drugs; 2015 Oct; 26(9):990-4. PubMed ID: 26241804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
    Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
    Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
    Fayette J; Boyle H; Chabaud S; Favier B; Engel C; Cassier P; Thiesse P; Méeus P; Sunyach MP; Vaz G; Ray-Coquard I; Ranchère D; Decouvelaere AV; Alberti L; Pérol D; Blay JY
    Anticancer Drugs; 2010 Jan; 21(1):113-9. PubMed ID: 19887935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.